Stock Track | XTALPI Soars 5.08% as Incubated Company's Drug Nominated for "Pharma Nobel Prize"

Stock Track

Aug 21

XTALPI (02228) saw its stock price surge by 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has received a prestigious nomination. The company's collaborative drug, SIGX1094R, has been nominated for the 2025 Prix Galien USA Award, often referred to as the "Nobel Prize of Pharmaceuticals," in the "Best Biotechnology Product" category.

This nomination marks a significant milestone for XTALPI and Signet Therapeutics, as SIGX1094R is the world's first targeted therapy for diffuse gastric cancer developed using an "organoid + AI" platform. The drug has already received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and is currently undergoing Phase I clinical trials. This recognition places Signet Therapeutics alongside global pharmaceutical giants such as Amgen, AstraZeneca, Johnson & Johnson, Pfizer, Merck, and Novartis.

The nomination highlights XTALPI's leadership in AI-powered drug discovery and its potential for future growth. As the first "18C stock" and "AI + robotics first stock" on the Hong Kong Stock Exchange, XTALPI's innovative approach to drug development has attracted partnerships with 16 of the world's top 20 pharmaceutical companies. With multiple pipelines in clinical trials and record-breaking collaborations, including a recent HK$47 billion deal with DoveTree, XTALPI's stock surge reflects investor confidence in the company's promising future in the AI pharmaceutical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162817936"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162817936\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162817936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 13:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162817936","market":"hk","top_or_hot":-1,"title":"Stock Track | XTALPI Soars 5.08% as Incubated Company's Drug Nominated for \"Pharma Nobel Prize\"","media":"Stock Track","content":"<p>XTALPI (02228) saw its stock price surge by 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has received a prestigious nomination. The company's collaborative drug, SIGX1094R, has been nominated for the 2025 Prix Galien USA Award, often referred to as the \"Nobel Prize of Pharmaceuticals,\" in the \"Best Biotechnology Product\" category.</p>\n\n<p>This nomination marks a significant milestone for XTALPI and Signet Therapeutics, as SIGX1094R is the world's first targeted therapy for diffuse gastric cancer developed using an \"organoid + AI\" platform. The drug has already received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and is currently undergoing Phase I clinical trials. This recognition places Signet Therapeutics alongside global pharmaceutical giants such as Amgen, AstraZeneca, Johnson & Johnson, Pfizer, Merck, and Novartis.</p>\n\n<p>The nomination highlights XTALPI's leadership in AI-powered drug discovery and its potential for future growth. As the first \"18C stock\" and \"AI + robotics first stock\" on the Hong Kong Stock Exchange, XTALPI's innovative approach to drug development has attracted partnerships with 16 of the world's top 20 pharmaceutical companies. With multiple pipelines in clinical trials and record-breaking collaborations, including a recent HK$47 billion deal with DoveTree, XTALPI's stock surge reflects investor confidence in the company's promising future in the AI pharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | XTALPI Soars 5.08% as Incubated Company's Drug Nominated for \"Pharma Nobel Prize\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | XTALPI Soars 5.08% as Incubated Company's Drug Nominated for \"Pharma Nobel Prize\"\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-21 13:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XTALPI (02228) saw its stock price surge by 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has received a prestigious nomination. The company's collaborative drug, SIGX1094R, has been nominated for the 2025 Prix Galien USA Award, often referred to as the \"Nobel Prize of Pharmaceuticals,\" in the \"Best Biotechnology Product\" category.</p>\n\n<p>This nomination marks a significant milestone for XTALPI and Signet Therapeutics, as SIGX1094R is the world's first targeted therapy for diffuse gastric cancer developed using an \"organoid + AI\" platform. The drug has already received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and is currently undergoing Phase I clinical trials. This recognition places Signet Therapeutics alongside global pharmaceutical giants such as Amgen, AstraZeneca, Johnson & Johnson, Pfizer, Merck, and Novartis.</p>\n\n<p>The nomination highlights XTALPI's leadership in AI-powered drug discovery and its potential for future growth. As the first \"18C stock\" and \"AI + robotics first stock\" on the Hong Kong Stock Exchange, XTALPI's innovative approach to drug development has attracted partnerships with 16 of the world's top 20 pharmaceutical companies. With multiple pipelines in clinical trials and record-breaking collaborations, including a recent HK$47 billion deal with DoveTree, XTALPI's stock surge reflects investor confidence in the company's promising future in the AI pharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1162817936","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162817936","pubTimestamp":1755752938,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"XTALPI (02228) saw its stock price surge by 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has received a prestigious nomination....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"个股追踪|孵化公司药物获“制药诺贝尔奖”提名XTALPI大涨5.08%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"XTALPI (02228) saw its stock price surge by 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has received a prestigious nomination. The company's collaborative drug, SIGX1094R, has been nominated for the 2025 Prix Galien USA Award, often referred to as the \"Nobel Prize of Pharmaceuticals,\" in the \"Best Biotechnology Product\" category.\nThis nomination marks a significant milestone for XTALPI and Signet Therapeutics, as SIGX1094R is the world's first targeted therapy for diffuse gastric cancer developed using an \"organoid + AI\" platform. The drug has already received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and is currently undergoing Phase I clinical trials. This recognition places Signet Therapeutics alongside global pharmaceutical giants such as Amgen, AstraZeneca, Johnson & Johnson, Pfizer, Merck, and Novartis.\nThe nomination highlights XTALPI's leadership in AI-powered drug discovery and its potential for future growth. As the first \"18C stock\" and \"AI + robotics first stock\" on the Hong Kong Stock Exchange, XTALPI's innovative approach to drug development has attracted partnerships with 16 of the world's top 20 pharmaceutical companies. With multiple pipelines in clinical trials and record-breaking collaborations, including a recent HK$47 billion deal with DoveTree, XTALPI's stock surge reflects investor confidence in the company's promising future in the AI pharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}